CAR T-cells plus antibody drug for relapsed large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests two immune-based treatments—first a special type of immunotherapy (CAR T-cells, called axi-cel), then a targeted antibody drug (glofitamab)—for people with large B-cell lymphoma that did not fully respond to their first treatment or came back within a year. The goal is to see if this combination can help more people achieve lasting remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your large B-cell lymphoma did not fully respond to your first treatment, or it came back within 12 months.
- Your first treatment must have included a drug like rituximab (Rituxan) and a type of chemotherapy called an anthracycline.
- You have not had CAR T-cell therapy or glofitamab before.
- Your heart, lungs, kidneys, and liver are working well enough, and you are in generally good health.
- You do not have active lymphoma in your brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines two treatments for large b-cell lymphoma that has come back or not responded to previous therapy. Glofitamab is a drug that helps the immune system attack cancer cells, and CAR-T therapy uses your own white blood cells, which are modified in a lab to find and kill cancer cells. This study aims to see if the two treatments together are safe and effective.
This study tests a combination of CAR-T cell therapy and a drug called glofitamab for people with large B-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combo can help those with high-risk features.
This trial tests whether adding a drug called glofitamab before and after CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) can improve outcomes for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if this combination can help you stay in remission longer.
This trial tests a new combination approach for people whose aggressive B-cell lymphoma has come back or not responded to treatment. It uses a bispecific antibody (a type of drug that helps immune cells attack cancer cells) followed by CAR-T cell therapy (reprogramming your own immune cells to find and kill cancer), sometimes with a stem cell transplant.
This trial tests a combination of two immunotherapy drugs (rimegepant and glofitamab) plus a special cell therapy called CD19 CAR-T for people with large B-cell lymphoma that has not responded to or has returned after previous treatment. The goal is to see if this combination can better control the lymphoma and improve outcomes.
This trial tests an experimental CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to find and attack cancer cells.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.